MYDA Advisors’s UroGen Pharma URGN Stock Holding History

MYDA Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,000	Closed	-$223K	–	178
2017 Q4	$223K	Buy	+6,000	New	+$214K	0.1%	129

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MYDA Advisors's URGN Position: Q1 2018 in Review

MYDA Advisors sold out of UroGen Pharma (URGN) in Q1 2018, closing a stake of 6,000 shares — an estimated $223K sold.

MYDA Advisors first reported a position in URGN in Q4 2017 and held it in 1 quarter. The position peaked at $223K in Q4 2017. 43 funds tracked by Wall St. Rank hold URGN as of Q1 2018.

MYDA Advisors reported no remaining UroGen Pharma position as of Q1 2018 after selling out during the quarter.
MYDA Advisors sold 6,000 UroGen Pharma shares in Q1 2018, an estimated $223K.
MYDA Advisors first reported a position in UroGen Pharma in Q4 2017 and held it in 1 quarter.
MYDA Advisors's UroGen Pharma position peaked at $223K in Q4 2017.
43 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.